Stocks Abbott Laboratories

More

  • NEW YORK— Abbott Laboratories on Wednesday reported sharply lower earnings for the first quarter compared with year-ago results that included a hefty gain on an asset sale. The average estimate of 12 analysts surveyed by Zacks Investment Research was for earnings of 39 cents per share. Eight analysts surveyed by Zacks expected $4.78 billion.

  • Faber Report: Abbott Labs to buy Alere

    CNBC's David Faber reports Abbott Labs is announcing it will buy diagnostics company Alere for $5.8 billion.

  • U.S. stock index futures indicated a mixed open Thursday after December durable goods orders declined far more than expected.

  • It was for a powerful antibiotic cocktail marketed in India by a unit of U.S. pharmaceutical giant Abbott Laboratories. And a government-appointed panel in India recommended to the Health Ministry last year that it not be approved for sale here, citing lack of safety and efficacy data and a high potential for "misuse." In fact, the drug has not been approved by the...

  • Shares of medtech companies such as Edwards Lifesciences, Boston Scientific and Becton Dickinson have outperformed the broad healthcare sector, and especially pharmaceutical and biotech shares, over the past two months since U.S. presidential candidate Hillary Clinton tweeted she planned to address specialty drug "price gouging." He said he likes...

  • Medtronic Plc, Abbott Laboratories, Edwards Lifesciences Corp and HeartWare International Inc in recent months have spent a total of $2 billion to buy young companies developing versions of the technology. Nearly 6 million people in the United States may suffer from mitral disease, and Wall Street analysts say it could be the next multibillion-dollar...

  • SANTIAGO, Nov 26- Chile's financial regulator said on Thursday it had fined Santiago- based businessman Juan Bilbao Hormaeche some $3.2 million for using insider information to trade shares of drug company CFR Pharmaceuticals SA. The move came about a month after the U.S. Securities and Exchange Commission reached a $13.2 million dollar settlement with...

  • Pfizer's proposed acquisition of Allergan will be one of the biggest tax inversions yet.

  • ORLANDO, Fla., Nov 9- Patients with severe leakage from the mitral valve of the heart who had the valve replaced had significantly lower rates of recurrence and heart failure two years after the procedure than those who underwent surgical repair, according to data presented on Monday. There was also a higher rate of reported heart failure events, 48 versus 29, and...

  • Twin boys Sun Qiyu and Sun Qichun hold China's national flags on the Tiananmen Gate in Beijing November 2, 2015. China must continue to enforce its one-child policy until new rules allowing all couples to have two children go into effect, the top family planning body said.

    China's easing of the one-baby rule may not be enough to cure its slowing fertility rate and aging population problem.

  • Traders on the Floor

    A hot sports car stock could leave a group of blue chips in its dust, as traders watch earnings reports to see if corporate profits are cooling.

  • NYSE Traders

    So far the earnings season has been lackluster, and some high-profile warnings have already given investors pause.

  • Brian Belski, chief investment strategist at BMO Capital Markets.

    Here's why there could be a "surprising" stock market rally in the fourth quarter, strategist Brian Belski said Monday.

  • Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    Allergan is considering a breakup of the company into two businesses, a person familiar with the matter told Reuters on Friday.

  • Traders work on the floor of the New York Stock Exchange.

    Big tech could put a damper on stocks Wednesday, after earnings took an ugly turn late Tuesday and Apple's stock was crushed after the closing bell.

  • Traders work on the floor of the New York Stock Exchange.

    Big tech could put a damper on stocks Wednesday, after earnings took an ugly turn late Tuesday and Apple's stock was crushed after the closing bell.

  • Johnson & Johnson products

    Jim Cramer makes the case as to why Johnson & Johnson cannot wait another day to break itself up.

  • Pharmaceutical drugs

    Automatic generic-drug substitution poses several big problems, says NYU Professor Melissa Schilling.

  • An employee works on a stent graft component in a sterile environment at the Medtronic assembly plant in Tijuana, Mexico.

    The health-care sector is hot, and investors don't have to bet on the riskiest biotech stocks to profit.